AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), Arcus Biosciences ((RCUS)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca and Arcus Biosciences are currently conducting a Phase III clinical study titled ‘A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy.’ The study aims to evaluate the efficacy and safety of combining durvalumab with domvanalimab compared to durvalumab with a placebo in treating Stage III unresectable non-small cell lung cancer (NSCLC).
The study tests two interventions: durvalumab, an immunotherapy drug, and domvanalimab, an anti-TIGIT antibody. These are administered via intravenous infusion every four weeks for up to 12 months, aiming to enhance the immune response against cancer cells.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to determine the effectiveness of the drug combination.
The study began on February 18, 2022, and is currently recruiting participants. The primary completion date is projected for July 23, 2025, which is also the date of the last update. These timelines are crucial for stakeholders to track the study’s progress and anticipate results.
This study could significantly impact AstraZeneca and Arcus Biosciences’ stock performance, as positive outcomes may enhance their market positions in the oncology sector. Investors should monitor this study closely, considering the competitive landscape in cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.